In short, Kalijn Bols' research entails the following:
Multimodal data fusion to guide the development of immunotherapies for uveal melanoma patients
Uveal melanoma occurs only in ~200 patients a year in the Netherlands and up to half of the patients with a primary uveal melanoma will develop metastases. Uveal melanoma differs clinically and genetically from cutaneous melanoma and response rates to immunotherapy are low. Previously, it was believed that the development of UM at an immune-privileged site, the eye, but infiltration of immune cells in uveal melanoma is present. In this project, we will analyze multiplex immunohistochemistry imaging and flow cytometry data of multiple patient cohorts to investigate tumor-immune interactions. To avoid the risk of overfitting our real data and overcome the challenges with multimodal data fusion, we will first develop and optimize our analysis approach using simulated data resembling real data. By optimal analysis of the combined data from multiple heterogeneous sources, we aim to obtain mechanistical understanding of immunological processes which will help develop strong theoretical rationales for clinical trials in the future to improve the outcome of uveal melanoma patients.
Hanarth Fonds Wolga 5 2491 BK Den HAAG Telephone: +31 70 20 60 177 Email: